Skip to main content
SpringerLink
Log in

Increased risk of mortality with paclitaxel-containing devices?

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. published in the Journal of the American Heart Association in December 2018 (K Katsanos et al).

References

  1. Health Products Regulatory Authority. Paclitaxel-coated balloons and Paclitaxel-eluting stents used for peripheral artery disease. Internet Document : [3 pages], 2 May 2019. Available from: URL: https://www.hpra.ie/docs/default-source/Safety-Notices/sn201913_variousmfrs_paclitaxel_v38414.pdf?sfvrsn=2

  2. Government of Canada. Paclitaxel-Coated Balloons (PCB) and Paclitaxel-Eluting Stents (PES) for the Treatment of Peripheral Arterial Disease (PAD) and the Potential Risk of Long-Term All-Cause Mortality. Internet Document : 6 May 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69848a-eng.php#fn1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Increased risk of mortality with paclitaxel-containing devices?. Reactions Weekly 1753, 2 (2019). https://doi.org/10.1007/s40278-019-61894-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-61894-1

Search

Navigation